MCID: AST007
MIFTS: 63

Astrocytoma malady

Neuronal diseases, Cancer diseases categories

Aliases & Classifications for Astrocytoma

About this section
Sources:
8Disease Ontology, 44Novoseek, 61UMLS, 39NCIt, 56SNOMED-CT, 33MeSH
See all sources

Aliases & Descriptions for Astrocytoma:

Name: Astrocytoma 8 44 61
Cerebral Astrocytoma 8 61
Astrocytoma, No Icd-O Subtype 8
Astrocytoma of Cerebrum 8
 
Astrocytoma of Brain 8
Astrocytic Tumor 8
Astroglioma 8


Classifications:



External Ids:

Disease Ontology8 DOID:3069
MeSH33 D001254

Summaries for Astrocytoma

About this section
Disease Ontology:8 A malignant glioma that is has material basis in astocyte cells, a type of star-shaped glial cell, located in the cerebrum.

MalaCards based summary: Astrocytoma, also known as cerebral astrocytoma, is related to subependymal giant cell astrocytoma and juvenile pilocytic astrocytoma. An important gene associated with Astrocytoma is KIAA1549 (KIAA1549), and among its related pathways are Advanced glycosylation endproduct receptor signaling and Inhibition of Ribosome Biogenesis by p14(ARF). The drugs cisplatin and cisplatin pwdr and the compounds reticulin and bcnu have been mentioned in the context of this disorder. Affiliated tissues include the cerebrum, brain and spinal cord, and related mouse phenotypes are pigmentation and normal.

Wikipedia:64 Astrocytomas are a type of cancer of the brain. They originate in a particular kind of glial cells,... more...

Related Diseases for Astrocytoma

About this section

Diseases in the Astrocytoma family:

Juvenile Astrocytoma

Diseases related to Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 303)
idRelated DiseaseScoreTop Affiliating Genes
1subependymal giant cell astrocytoma32.1S100B, SYP
2juvenile pilocytic astrocytoma31.9TNC
3tuberous sclerosis31.6S100B, SYP, NES, PTEN, GFAP
4gemistocytic astrocytoma31.5S100B, PTEN, GFAP
5neuroblastoma31.3SYP, TP53
6oligoastrocytoma31.3GFAP, MGMT
7ganglioglioma31.1S100B, SYP, GFAP
8pilocytic astrocytoma31.0CDK4, S100B, OLIG2, SYP, LGALS3, NES
9oligodendroglioma31.0EGFR, CDKN2A, OLIG2, TP73, PTEN, GFAP
10dysembryoplastic neuroepithelial tumor30.9KIAA1549, OLIG2, SYP
11gliosarcoma30.8CDK4, PTEN, GFAP
12medulloblastoma30.8CDK4, S100B, SYP, NES, TP73, TP53
13ependymoma30.8EGFR, S100B, SYP, NES, TP73, GFAP
14glioblastoma multiforme30.7EGFR, CDK4, CDKN2A, NES, TP53, PTEN
15gangliocytoma30.7SYP, PTEN
16renal cell carcinoma30.7EGFR, TP53
17giant cell glioblastoma30.7EGFR, PTEN, GFAP
18gliomatosis cerebri30.6PTEN, GFAP
19central neurocytoma30.6OLIG2, SYP, GFAP
20myxopapillary ependymoma30.5S100B, GFAP
21pineoblastoma30.5SYP, GFAP
22hemangioblastoma30.5S100B, SYP, NES, GFAP
23choroid plexus carcinoma30.5S100B, GFAP
24li-fraumeni syndrome30.4CDKN2A, TP53
25brain cancer30.4EGFR, MGMT
26chordoma30.4S100B, LGALS3, GFAP
27neurilemmoma30.4S100B, NES, GFAP
28mesothelioma30.3CDK4, CDKN2A, TNC
29pleomorphic adenoma30.3S100B, PCNA, TNC, GFAP
30neurofibroma30.3S100B, SYP, TP73, TNC
31b-cell lymphomas30.2CDK4, CDKN2A, TP53, MGMT
32papilloma30.1CDKN2A, PCNA, TP73, TP53
33anaplastic oligodendroglioma30.1EGFR, CDK4, CDKN2A, OLIG2, LGALS3, PTEN
34retinoblastoma30.0EGFR, CDK4, CDKN2A, PCNA, SYP, TP73
35glioblastoma30.0EGFR, CDK4, CDKN2A, S100B, OLIG2, PCNA
36pituitary adenoma30.0CDK4, PCNA, SYP, LGALS3, NES, TP73
37breast cancer29.9PCNA, TP53
38leukemia29.9CDK4, CDKN2A, OLIG2, NES, TP73, TP53
39grade iii astrocytoma29.9EGFR, CDK4, CDKN2A, OLIG2, PCNA, LGALS3
40colorectal cancer29.8EGFR, CDK4, LGALS3, TP73, TP53, IGFBP2
41adenoma29.7CDK4, CDKN2A, PCNA, SYP, LGALS3, NES
42malignant glioma29.5EGFR, CDK4, CDKN2A, KIAA1549, OLIG2, PCNA
43prostate cancer29.5EGFR, CDK4, PCNA, LGALS3, NES, TP73
44melanoma29.3CDK4, CDKN2A, S100B, PCNA, LGALS3, NES
45adenocarcinoma29.3EGFR, CDK4, CDKN2A, PCNA, SYP, LGALS3
46cerebellar astrocytoma10.8
47pilomyxoid astrocytoma10.7
48spinal cord astrocytoma10.7
49fibrillary astrocytoma10.6
50ependymoblastoma10.6GFAP

Graphical network of the top 20 diseases related to Astrocytoma:



Diseases related to astrocytoma

Symptoms for Astrocytoma

About this section

Drugs & Therapeutics for Astrocytoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Afinitor13 38 EVEROLIMUS Novartis Approved March 2009
FDA Label: Afinitor
Malady that Drug Treats: renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumor
Indications and Usage:13 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:11 Serine/threonine-protein kinase mTOR
Mechanism of Action:13 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the; PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular; protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of; mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiation; factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate of; mTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independent; activation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and; reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown; to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.; Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitro; studies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,; and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activity; of everolimus in a synergistic manner.; Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).; Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,; inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.
2
Temodar13 38 TEMOZOLOMIDE Schering-Plough Approved August 1999
FDA Label: Temodar
Malady that Drug Treats: refractory anaplastic astrocytoma
Indications and Usage:13 TEMODAR is an alkylating drug indicated for the treatment of adult; patients with:; Newly diagnosed glioblastoma multiforme (GBM) concomitantly; with radiotherapy and then as maintenance treatment. (1.1); Refractory anaplastic astrocytoma patients who have experienced; disease progression on a drug regimen containing nitrosourea; and procarbazine. (1.2)
DrugBank Targets:11 1. DNA
Mechanism of Action:13 
Target: DNA
Action: alkylizer
FDA: Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound; 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to alkylation of; DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine. ;

Drug clinical trials:

Search ClinicalTrials for Astrocytoma

Search NIH Clinical Center for Astrocytoma

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Astrocytoma

About this section

Anatomical Context for Astrocytoma

About this section

MalaCards organs/tissues related to Astrocytoma:

31
Brain, Spinal cord, Endothelial, Cerebellum, Pineal, Pituitary, Cortex, Temporal lobe, Thyroid, Breast, Colon, Ovary, Testes, Monocytes, Eye, Bone, Retina, Lung, Testis, T cells, Hypothalamus, Medulla oblongata, Tongue, Bone marrow, Liver, Skin, Prostate, Myeloid, B cells, Prefrontal cortex

FMA organs/tissues related to Astrocytoma:

14
The cerebrum

Animal Models for Astrocytoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Astrocytoma:

35 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.7EGFR, CDKN2A, TP53, PTEN
2MP:00028739.2SYP, GFAP, PTEN, EGFR, S100B, TP53
3MP:00107719.2EGFR, CDK4, PTEN, TP53, LGALS3, S100B
4MP:00053699.2PTEN, GFAP, OLIG2, EGFR, TP53, CDK4
5MP:00053819.2EGFR, CDK4, CDKN2A, LGALS3, TP73, TP53
6MP:00053709.2CDK4, CDKN2A, TP53, PTEN, IGFBP2, EGFR
7MP:00053889.1TP53, TP73, LGALS3, EGFR, CDKN2A, PTEN
8MP:00020069.1OLIG2, MGMT, PTEN, TP53, TP73, CDKN2A
9MP:00053679.1IGFBP2, PTEN, TP53, LGALS3, CDK4, EGFR
10MP:00053809.1TP53, EGFR, CDK4, CDKN2A, NES, TP73
11MP:00053919.1EGFR, GFAP, PTEN, TP53, TP73, OLIG2
12MP:00030129.1NRN1, OLIG2, PCNA, SYP, TP53, MGMT
13MP:00053909.1EGFR, CDKN2A, PTEN, TP53, LGALS3, TP73
14MP:00053799.1EGFR, CDK4, CDKN2A, PCNA, TP73, TP53
15MP:00053859.0EGFR, CDK4, TP73, TP53, LGALS3, GFAP
16MP:00053759.0EGFR, OLIG2, PCNA, TP53, PTEN
17MP:00053899.0PCNA, EGFR, CDK4, PTEN, TP53, CDKN2A
18MP:00053868.7CDKN2A, GFAP, S100B, TNC, CDK4, PTEN
19MP:00053768.6MGMT, IDH1, CDK4, GFAP, PTEN, TNC
20MP:00053848.6EGFR, PTEN, GFAP, TP53, TP73, NES
21MP:00053978.5TP53, EGFR, CDK4, TP73, IGFBP2, PCNA
22MP:00053788.4TP73, CDK4, CDKN2A, NES, PCNA, EGFR
23MP:00053878.4GFAP, EGFR, CDK4, CDKN2A, LGALS3, IGFBP2
24MP:00036318.2TP53, NRN1, TP73, NES, TNC, LGALS3
25MP:00107688.2EGFR, TP73, TP53, PTEN, LGALS3, MGMT

Publications for Astrocytoma

About this section

Articles related to Astrocytoma:

(show top 50)    (show all 1966)
idTitleAuthorsYear
1
Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma. (25909089)
2015
2
Expression and functional significance of ezrin in human brain astrocytoma. (23712870)
2013
3
The genetic landscape of anaplastic astrocytoma. (24140581)
2013
4
Transformation of adult cerebellar pilocytic astrocytoma to glioblastoma. (23884731)
2013
5
Expression and biological role of CIP2A in human astrocytoma. (23467938)
2013
6
Correlation of aquaporin-1 water channel protein expression with tumor angiogenesis in human astrocytoma. (23393355)
2013
7
Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma. (22825389)
2012
8
Cerebellar metastasis from serous adenocarcinoma of the ovary mimicking pilocytic astrocytoma. (23293670)
2012
9
Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance. (21978279)
2012
10
I^-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas. (22505738)
2012
11
Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells. (21208252)
2011
12
Intracranial metastasis of spinal intramedullary anaplastic astrocytoma. (22347337)
2011
13
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT. (20569675)
2010
14
Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells. (19357230)
2009
15
Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. (19332096)
2009
16
Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? (18000757)
2008
17
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. (18713462)
2008
18
Progression of astrocytomas and meningiomas: an evaluation in vitro. (17227292)
2007
19
Congenital diffuse anaplastic astrocytoma with ependymal and leptomeningeal spread: case report. (17443288)
2007
20
Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. (17634619)
2007
21
Spinal cord astrocytoma presenting as "idiopathic" intracranial hypertension. (16298472)
2006
22
Immunohistochemical detection of epidermal growth factor receptor in human high-grade astrocytomas--a comparison between frozen- and paraffin sections. (15943037)
2005
23
Immunocytochemical detection of members of the caspase cascade of apoptosis in high-grade astrocytomas. (15523899)
2004
24
Role of phospholipase D signaling in ethanol-induced inhibition of carbachol-stimulated DNA synthesis of 1321N1 astrocytoma cells. (15255942)
2004
25
Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. (15367334)
2004
26
Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors. (12724228)
2003
27
Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. (14581362)
2003
28
Muscarinic receptor-mediated activation of p70 S6 kinase 1 (S6K1) in 1321N1 astrocytoma cells: permissive role of phosphoinositide 3-kinase. (12747804)
2003
29
Stromelysin-1/matrix metalloproteinase-3 (MMP-3) expression accounts for invasive properties of human astrocytoma cell lines. (12866026)
2003
30
Desmoplastic infantile astrocytoma and ganglioglioma: a search for genomic characteristics. (12111357)
2002
31
Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas. (11119125)
2000
32
Expression and regulation of neuropilin-1 in human astrocytomas. (11058875)
2000
33
Spinal cord astrocytoma: response to PCV chemotherapy. (10668731)
2000
34
Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. (10554042)
1999
35
Astrocytoma cell interaction with elastin substrates: implications for astrocytoma invasive potential. (9890632)
1999
36
Glial fibrillary acidic protein and its fragments discriminate astrocytoma from oligodendroglioma. (10344289)
1999
37
Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma? (10630353)
1999
38
Astrocytomas and choroid plexus tumors in two families with identical p53 germline mutations. (9825943)
1998
39
A new factor derived from 1321N1 human astrocytoma cells causes differentiation of PC-12 cells mediated through mitogen-activated protein kinase cascade. (9739111)
1998
40
The importance of cell density in the interpretation of growth factor effects on collagenase IV activity release and extracellular matrix production from C6 astrocytoma cells. (9821106)
1998
41
Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. (9568761)
1998
42
Keratin expression in astrocytomas: an immunofluorescent and biochemical reassessment. (9293896)
1997
43
Immunohistochemical characterization of subependymal giant cell astrocytomas. (8928613)
1996
44
Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. (8290551)
1994
45
Simultaneous quantitation of cytokine mRNAs in interleukin-1 beta stimulated U373 human astrocytoma cells by a polymerisation chain reaction method involving co-amplification with an internal multi-specific control. (1296803)
1992
46
Epidermal growth factor and other mitogens induce binding of a protein complex to the c-fos serum response element in human astrocytoma and other cells. (1902475)
1991
47
Ras p21 expression in brain tumors: elevated expression in malignant astrocytomas and glioblastomas multiforme. (1667267)
1991
48
Intracranial metastasis of a spinal cord astrocytoma--case report. (1694278)
1990
49
Multiple primary intracranial tumors of different cell types: association of anaplastic astrocytoma and acoustic neurinoma--with review of the literature. (7179095)
1982
50
Gemistocytic astrocytoma: cytological observations on the rate of hydrolysis of some phosphoric acid esters. (13301910)
1955

Variations for Astrocytoma

About this section

Cosmic variations for Astrocytoma:

6
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
144653TP53central nervous system,spinal cord,glioma,astrocytoma Grade IV3

Expression for genes affiliated with Astrocytoma

About this section
Search GEO for disease gene expression data for Astrocytoma.

Pathways for genes affiliated with Astrocytoma

About this section

Pathways related to Astrocytoma according to GeneCards Suite gene sharing:

(show all 42)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
110.1LGALS3, S100B
210.1CDKN2A, TP53
3
Show member pathways
Prostate Cancer36
Integrated Cancer pathway36
Steroid Biosynthesis36
9.9TP53, PTEN, CDK4
4
Show member pathways
9.9CDK4, TP53, PTEN
59.9PTEN, TP53, CDK4
69.9TP53, CDK4, TP73
79.9TP53, CDK4, CDKN2A
89.9CDK4, CDKN2A, TP53
9
Show member pathways
9.9CDK4, CDKN2A, TP53
10
Show member pathways
9.8TP53, TP73, CDKN2A
11
Show member pathways
Apoptosis Modulation and Signaling36
Apoptosis36
9.8CDKN2A, TP53, TP73
129.8TNC, S100B, SYP, GFAP
13
Show member pathways
9.8TP53, CDK4, PCNA
149.8CDK4, TP53, PCNA
159.8CDK4, PCNA, TP53
169.8TP53, PCNA, CDK4
17
Show member pathways
9.8PTEN, GFAP, S100B, EGFR
18
Show member pathways
9.8EGFR, TNC, PTEN, TP53
199.7PTEN, CDK4, EGFR, TP53
209.7CDK4, EGFR, PTEN, TP53
21
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
9.7EGFR, TP53, TP73, PTEN
22
Show member pathways
9.7CDKN2A, TP53, CDK4, EGFR
23
Show member pathways
DNA damage response (only ATM dependent)36
Wnt Signaling Pathway and Pluripotency36
9.7TP73, CDKN2A, TP53, PTEN
24
Show member pathways
Toll-like receptor signaling pathway36
Regulation of toll-like receptor signaling pathway36
9.6PCNA, CDK4, TP53, PTEN
25
Show member pathways
Signal transduction PTEN pathway59
9.6TP53, EGFR, PCNA, PTEN
269.6TP53, PCNA, CDKN2A, PTEN
279.6EGFR, CDK4, TP53, PTEN, TNC
289.6TP53, CDKN2A, PCNA, CDK4
29
Show member pathways
9.6CDK4, CDKN2A, PCNA, TP53
30
Show member pathways
Cell cycle36
9.6CDKN2A, TP53, PCNA, CDK4
31
Show member pathways
Development IGF RI signaling
Immune response IL 4 signaling pathway59
Signal transduction AKT signaling59
9.5PCNA, TP53, IGFBP2, PTEN
329.5TP53, GFAP, LGALS3, EGFR, CDK4
339.5PTEN, CDKN2A, TP53, EGFR, TNC
34
Show member pathways
Signaling Pathways in Glioblastoma36
9.5PTEN, CDKN2A, CDK4, TP53, EGFR
359.5TP53, CDKN2A, CDK4, EGFR, PTEN
36
Show member pathways
DNA damage response36
9.5PTEN, CDKN2A, CDK4, TP73, TP53
379.4EGFR, PTEN, TP53, CDK4, PCNA
389.4PCNA, EGFR, TP53, TP73, PTEN
399.3TP53, EGFR, CDK4, CDKN2A, PTEN, MGMT
40
Show member pathways
9.2CDKN2A, CDK4, EGFR, TP53, TNC, GFAP
41
Show member pathways
9.2MGMT, TP73, PCNA, CDKN2A, CDK4, TP53

Compounds for genes affiliated with Astrocytoma

About this section

Compounds related to Astrocytoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 160)
idCompoundScoreTop Affiliating Genes
1reticulin4410.0GFAP, S100B, PCNA, SYP
2bcnu4410.0EGFR, MGMT, CDKN2A, TP53, GFAP
3olomoucine44 1110.9CDK4, CDKN2A, PCNA, TP53
4dutp449.8PCNA, SYP, LGALS3, TP53, GFAP
5crcs449.8MGMT, TP53, CDKN2A, PTEN
6o6-methylguanine449.8CDKN2A, MGMT, PCNA, TP73, TP53
7silver449.7CDKN2A, PCNA, SYP, TNC, GFAP
8deoxyribonucleic acid449.7MGMT, IGFBP2, PTEN, PCNA, CDKN2A
9gemcitabine44 50 1111.6TP53, PCNA, EGFR, TP73, PTEN
10vincristine44 50 1111.6TP53, TP73, MGMT, CDKN2A, PTEN
11temozolomide44 1110.6NES, TP53, EGFR, CDKN2A, PCNA, MGMT
12thymidylate449.6CDK4, CDKN2A, TP53, MGMT, EGFR, PCNA
13agar449.6CDK4, EGFR, CDKN2A, LGALS3, PTEN, GFAP
14egcg449.6CDKN2A, EGFR, TP53, PCNA, CDK4, MGMT
15bromodeoxyuridine449.5GFAP, CDK4, S100B, PCNA, NES, IGFBP2
16camptothecin44 60 1111.5CDKN2A, PCNA, TP53, TP73, MGMT, CDK4
175-aza-2deoxycytidine449.5PTEN, CDKN2A, TP53, TP73, MGMT, PCNA
18etoposide44 50 60 1112.5TP53, SYP, PTEN, PCNA, S100B, LGALS3
19hematoxylin449.5CDKN2A, GFAP, PCNA, PTEN, S100B, LGALS3
20glycogen44 2410.4IGFBP2, GFAP, PTEN, LGALS3, SYP, CDK4
21doxorubicin44 50 1111.4EGFR, TP53, TP73, CDKN2A, CDK4, PTEN
22thymidine44 2410.3GFAP, IGFBP2, S100B, MGMT, PCNA, TP53
23butyrate449.3PCNA, GFAP, CDKN2A, TP53, LGALS3, CDK4
24leucine449.3CDK4, CDKN2A, IGFBP2, GFAP, PTEN, S100B
25formaldehyde44 2410.3MGMT, PCNA, SYP, S100B, TNC, GFAP
26ly294002449.3EGFR, CDK4, TP53, PTEN, IGFBP2, TNC
27genistein44 28 60 1 24 1114.3CDK4, CDKN2A, PCNA, SYP, PTEN, GFAP
28cycloheximide449.3IGFBP2, TNC, CDKN2A, PTEN, EGFR, GFAP
295fluorouracil449.2PTEN, EGFR, CDKN2A, MGMT, PCNA, TP73
30nitric oxide44 24 1111.2CDKN2A, LGALS3, MGMT, CDK4, SYP, NES
31paclitaxel44 50 1111.1PCNA, S100B, CDKN2A, MGMT, CDK4, GFAP
32mg 13244 6010.1PCNA, CDKN2A, EGFR, TP53, PTEN
33dexamethasone44 50 28 1112.0MGMT, TNC, GFAP, PCNA, S100B, CDKN2A
34glutamate449.0LGALS3, PCNA, IDH1, GFAP, TNC, NES
35testosterone44 60 24 1112.0EGFR, IGFBP2, PCNA, GFAP, SYP, S100B
36cysteine448.9GFAP, MGMT, PTEN, LGALS3, CDK4, CDKN2A
37h2o2448.9TNC, PTEN, TP53, LGALS3, SYP, CDKN2A
38oxygen44 249.8CDKN2A, CDK4, IGFBP2, GFAP, PTEN, NES
39lipid448.8TNC, PTEN, TP73, GFAP, IGFBP2, S100B
40arginine448.8TP73, GFAP, PTEN, PCNA, CDK4, CDKN2A
41oligonucleotide448.7MGMT, IGFBP2, PTEN, TP53, TNC, CDK4
42serine448.7S100B, CDKN2A, EGFR, SYP, TNC, IGFBP2
43cisplatin44 50 60 1111.7EGFR, CDK4, CDKN2A, PCNA, SYP, LGALS3
44tyrosine448.7IGFBP2, GFAP, EGFR, CDK4, S100B, SYP
45calcium44 50 24 1111.5IDH1, GFAP, IGFBP2, LGALS3, MGMT, TNC
46paraffin448.1CDK4, EGFR, CDKN2A, S100B, PCNA, MGMT
47progesterone44 28 60 24 1111.9IGFBP2, PTEN, TP53, TP73, NES, LGALS3
48vegf447.9EGFR, LGALS3, MGMT, IGFBP2, GFAP, TNC
49estrogen447.9IGFBP2, EGFR, CDK4, PCNA, S100B, CDKN2A
50retinoic acid44 248.5TNC, GFAP, IGFBP2, MGMT, PTEN, TP53

GO Terms for genes affiliated with Astrocytoma

About this section

Cellular components related to Astrocytoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1chromatinGO:00007859.9CDK4, TP73, TP53
2cytoplasmGO:00057377.7TRIM47, IDH1, GFAP, PTEN, TP53, NES
3nucleusGO:00056347.5LGALS3, TP73, TP53, PTEN, MGMT, PCNA

Biological processes related to Astrocytoma according to GeneCards Suite gene sharing:

(show all 21)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of cell sizeGO:004579310.3TP73, CDK4
2long-term synaptic potentiationGO:006029110.3GFAP, PTEN, S100B
3regulation of neuronal synaptic plasticityGO:004816810.3SYP, S100B
4mitotic G1 DNA damage checkpointGO:003157110.3TP53, TP73
5replicative senescenceGO:009039910.3TP53, CDKN2A
6learning or memoryGO:000761110.3PTEN, EGFR, S100B
7response to ethanolGO:004547110.3PTEN, MGMT, TNC
8DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.2TP73, TP53
9digestive tract morphogenesisGO:004854610.2TP73, EGFR
10positive regulation of oligodendrocyte differentiationGO:004871410.1OLIG2, TP73
11central nervous system developmentGO:000741710.1PTEN, TP53, NES, S100B
12positive regulation of cell cycle arrestGO:007115810.1TP53, CDKN2A
13response to X-rayGO:001016510.0TP73, TP53
14mismatch repairGO:00062989.9TP73, PCNA
15cell cycle arrestGO:00070509.9CDKN2A, TP73, TP53
16response to drugGO:00424939.9MGMT, IGFBP2, PTEN, CDK4
17positive regulation of cell proliferationGO:00082849.9TNC, PTEN, S100B, CDK4, EGFR
18positive regulation of apoptotic processGO:00430659.9TP73, PTEN, CDK4, S100B, TP53
19phosphatidylinositol-mediated signalingGO:00480159.9EGFR, PCNA, PTEN
20cell proliferationGO:00082839.8S100B, PCNA, TP53, PTEN, EGFR
21G1/S transition of mitotic cell cycleGO:00000829.4CDKN2A, PCNA, CDK4

Molecular functions related to Astrocytoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MDM2/MDM4 family protein bindingGO:009737110.1CDKN2A, TP53
2p53 bindingGO:00020399.5CDKN2A, TP73, TP53
3protein kinase bindingGO:00199019.4PTEN, TP53, TP73, CDKN2A, EGFR
4identical protein bindingGO:00428029.2EGFR, S100B, PCNA, SYP, TP73, TP53

Sources for Astrocytoma

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet